Final results regarding the addition of dendritic cell vaccines to neoadjuvant chemotherapy in early HER2-negative breast cancer patients: clinical and translational analysis
/in Breast Cancer, Dendritic Cells, International Publications /von 2021-12-23 / Ther Adv Med Oncol 2021;13:17588359211064653Oncolytic viruses: A novel treatment strategy for breast cancer
/in Breast Cancer, International Publications, Newcastle Disease Virus /von 2021-12-16 / Genes Dis 2023 Mar;10(2):430-446Phase I Clinical Trial of an Autologous Dendritic Cell Vaccine Against HER2 Shows Safety and Preliminary Clinical Efficacy
/in Breast Cancer, Dendritic Cells, International Publications /von 2021-12-16 / Front Oncol 2021;11:789078The Immune Landscape of Breast Cancer: Strategies for Overcoming Immunotherapy Resistance
/in Breast Cancer, International Publications /von 2021-11-29 / Cancers (Basel) 2021 Nov;13(23)Autologous Dendritic Cells in Combination With Chemotherapy Restore Responsiveness of T Cells in Breast Cancer Patients: A Single-Arm Phase I/II Trial
/in Breast Cancer, Dendritic Cells, International Publications /von 2021-08-20 / Front Immunol 2021;12:669965Dendritic Cells Pulsed with Cytokine-Adjuvanted Tumor Membrane Vesicles Inhibit Tumor Growth in HER2-Positive and Triple Negative Breast Cancer Models
/in Breast Cancer, Dendritic Cells, International Publications /von 2021-08-04 / Int J Mol Sci 2021 Aug;22(16)Prognostic Factors for Advanced/Recurrent Breast Cancer Treated With Immune-cell Therapy
/in Breast Cancer, Dendritic Cells, International Publications /von 2021-08-01 / Anticancer Res 2021 Aug;41(8):4133-4141Prophylactic Dendritic Cell Vaccination in Experimental Breast Cancer Controls Immunity and Hepatic Metastases
/in Breast Cancer, Dendritic Cells, International Publications /von 2021-07-01 / Anticancer Res 2021 Jul;41(7):3419-3427CD133 mRNA-transfected dendritic cells induce coordinated cytotoxic and helper T cell responses against breast cancer stem cells
/in Breast Cancer, Dendritic Cells, International Publications /von 2021-05-19 / Mol Ther Oncolytics 2021 Sep;22:64-71
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de